The American Journal of Medicine
Volume 121, Issue 8, Supplement 2 , Pages S18-S26 , August 2008

Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms in African Americans and Latinos: Treatment in the Context of Common Comorbidities

  • Ivan Colon, MD

      Affiliations

    • Department of Urology, Downstate Medical Center, Brooklyn, New York, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Ivan Colon, MD, Department of Urology, Downstate Medical Center, 450 Clarkson Avenue, Box 79, Brooklyn, New York 11203.
    • ,
  • Richard E. Payne, MD

      Affiliations

    • North Coast Family Medical Group, Encinitas, California, USA

References 

  1. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993;150:85–89
  2. Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology. 2002;59:245–250
  3. Sarma AV, McLaughlin JC, Jacobsen SJ, et al. Health-seeking behavior and lower urinary tract symptoms among a cohort of African-American men: the Flint Men's Health Study. Presented at the 2004 American Urological Association Annual Meeting, May 8–13, San Francisco, CA. Abstract 1547. http://www.abstracts2view.com/aua_archive/view.php?nu=2004005247Accessed May 17, 2008
  4. Sarma AV, Wei JT, Jacobson DJ, et al. Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men's Health Study. Urology. 2003;61:1086–1091
  5. Roehrborn CG, Logie JW, Blackman N, et al. Racial differences in the risk of BPH progression and prostate cancer. Presented at the 2004 American Urological Association Annual Meeting, May 8–13, San Francisco, CA. Abstract 1549. http://www.abstracts2view.com/aua_archive/view.php?nu=200793512Accessed
  6. Aoki Y, Arai Y, Maeda H, Okubo K, Shinohara K. Racial differences in cellular composition of benign prostatic hyperplasia. Prostate. 2001;49:243–250
  7. Kaplan SA, Reis RB, Staiman VB, Te AE. Is the ratio of transition zone to total prostate volume higher in African-American men than in their Caucasian or Hispanic counterparts?. Br J Urol. 1998;82:804–807
  8. Salam MT, Ursin G, Skinner EC, Dessissa T, Reichardt JK. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol Oncol. 2005;23:246–253
  9. Michel MC, Heemann U, Schumacher H, Mehlburger L, Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol. 2004;172:1390–1393
  10. Hammarsten J, Högstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press. 1999;8:29–36
  11. Hytrin [package insert]. North Chicago, IL: Abbott Laboratories; 2001;
  12. Cardura [package insert]. New York: Pfizer Roerig; 2002;
  13. Farmer RDT, Clifford GM. Effects of prescribing α1-blockers for LUTS on the medical management of hypertension. 2001 American Urological Association Annual Meeting, June 2–7, Anaheim, CA. Abstract 1563. http://www.abstracts2view.com/aua_archive/J Urol 2001 May;165(5 suppl):1-418. Accessed
  14. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? (A meta-analysis). Lancet. 2005;366:1545–1553
  15. Kramer H, Han C, Post W, et al. Racial/ethnic differences in hypertension and hypertension treatment and control in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Hypertens. 2004;17:963–970
  16. Van Dijk MM, Skrekas T, Wijkstra H, et al. Lower urinary tract symptoms and sexual dysfunction: a confirmed association. Presented at the 2005 American Urological Association Annual Meeting, May 21–26, San Antonio, TX. Abstract 1292. http://www.abstracts2view.com/aua_archive/viewphp?nu=20054236also in print J Urol 2005 Apr;173(4 suppl):1467. Accessed
  17. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol. 2003;44:637–649
  18. ALF-ONE Study GroupNickel JC, Elhilali M, Vallancien G. Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH. BJU Int. 2005;95:571–574
  19. Barqawi A, O'Donnell C, Kumar R, Koul H, Crawford ED. Correlation between LUTS (AUA-SS) and erectile dysfunction (SHIM) in an age-matched racially diverse male population: data from the Prostate Cancer Awareness Week (PCAW). Int J Impot Res. 2005;17:370–374
  20. Parsons JK, Carter HB, Partin AW, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91:2562–2568
  21. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol. 2001;39:151–158
  22. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int. 2006;97(suppl 2):23–28
  23. Hammarsten J, Hogstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998;1:157–162
  24. Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta. 2006;370:89–93
  25. Berger AP, Deibl M, Leonhartsberger N, et al. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int. 2005;96:1073–1078
  26. Ferrannini E, Gastaldelli A, Matsuda M, et al. Influence of ethnicity and familial diabetes on glucose tolerance and insulin action: a physiological analysis. J Clin Endocrinol Metab. 2003;88:3251–3257
  27. Harris MI, Flegal KM, Cowie CC. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults (The Third National Health and Nutrition Examination Survey, 1988-1994). Diabetes Care. 1998;21:518–524
  28. Young BA, Maynard C, Boyko EJ. Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. Diabetes Care. 2003;26:2392–2399
  29. Young BA, Maynard C, Reiber G, Boyko EJ. Effects of ethnicity and nephropathy on lower-extremity amputation risk among diabetic veterans. Diabetes Care. 2003;26:495–501
  30. Gonzalez RR, Kaplan SA. First-line treatment for symptomatic benign prostatic hyperplasia: is there a particular patient profile for a particular treatment?. World J Urol. 2006;24:360–366
  31. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003) (Chapter 1: diagnosis and treatment recommendations). J Urol. 2003;170:530–547
  32. Gee WF, Holtgrewe HL, Blute ML, et al. 1997 American Urological Association Gallup survey: changes in diagnosis and management of prostate cancer and benign prostatic hyperplasia, and other practice trends from 1994 to 1997. J Urol. 1998;160:1804–1807
  33. Harkaway RC, Issa MM. Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2006;9:204–214
  34. Narayan P, O'Leary MP, Davidai G. Early efficacy of tamsulosin versus terazosin in the treatment of men with benign prostatic hyperplasia: a randomized, open-label trial. J Appl Res. 2005;5:237–245
  35. Caine M. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol. 1986;136:1–4
  36. Roehrborn CG, Schwinn DA. α1-Adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004;171:1029–1035
  37. ALFORTI Study Groupvan Kerrebroeck P, Jardin A, Laval KU, van Cargh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol. 2000;37:306–313
  38. Flomax [package insert]. Ridgefield, CT: Boehringer-Ingelheim Pharmaceuticals, Inc; 2005;
  39. Hatano A, Takahashi H, Tamaki M, Komeyama T, Koizumi T, Takeda M. Pharmacological evidence of distinct α1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol. 1994;113:723–728
  40. Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther. 1997;19:730–742
  41. Kaplan SA, Neutel J. Vasodilatory factors in treatment of older men with symptomatic benign prostatic hyperplasia. Urology. 2006;67:225–231
  42. European Tamsulosin Study GroupBuzelin JM, Fonteyne E, Kontturi M, Witjes WP, Khan A. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br J Urol. 1997;80:597–605
  43. Avodart [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2005;
  44. Proscar [package insert]. Whitehouse Station, NJ: Merck & Co; 2004;
  45. Roehrborn CG, Lukkarinen O, Mark S, Siami P, Ramsdell J, Zinner N. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5α-reductase inhibitor dutasteride: results of 4-year studies. BJU Int. 2005;96:572–577
  46. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia (Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group). N Engl J Med. 1996;335:533–539
  47. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387–2398
  48. Kaplan SA, McConnell JD, Roehrborn CG, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol. 2006;175:217–220
  49. Jaffe WI, Te AE. Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment. Curr Urol Rep. 2005;6:410–418
  50. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296:2319–2328
  51. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003;169:2253–2256
  52. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int. 2004;94:817–820
  53. Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006;354:557–566
  54. Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA. 1998;280:1604–1609
  55. Ishani A, MacDonald R, Nelson D, Rutks I, Wilt TJ. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. Am J Med. 2000;109:654–664
  56. Donkervoort T, Sterling A, van Ness J, Donker PJ. A clinical and urodynamic study of tadenan in the treatment of benign prostatic hypertrophy. Eur Urol. 1977;3:218–225
  57. Chatelain C, Autet W, Brackman F. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. Urology. 1999;54:473–478
  58. Tan A, Liao C, Mo Z, Cao Y. Meta-analysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction. Br J Surg. 2007;94:1201–1208
  59. Alivizatos G, Skolarikos A. Greenlight laser in benign prostatic hyperplasia: turning green into gold. Curr Opin Urol. 2008;18:46–49
  60. Patel A, Fuchs GJ, Gutierrez-Acéves J, Andrade-Perez F. Completeness and efficiency of prostate tissue removal: loop resection compared with a new operative technique of transurethral electrovaporization. BJU Int. 1999;84:43–49
  61. Liu CK, Lee WK, Ko MC, Jeng HS, Chiang HS, Yu HJ. Transurethral RollerLoop vapor resection of prostate for treatment of symptomatic benign prostatic hyperplasia: a 2-year follow-up study. Scand J Urol Nephrol. 2006;40:409–415
  62. Ho HS, Cheng CW. Bipolar transurethral resection of prostate: a new reference standard?. Curr Opin Urol. 2008;18:50–55
  63. Hill B, Belville W, Bruskewitz R, et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol. 2004;171:2336–2340
  64. Gupta N, Sivaramakrishna , Kumar R, Dogra PN, Seth A. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 g. BJU Int. 2006;97:85–89
  65. Platz EA, Kawachi I, Rimm EB, Willett WC, Giovannucci E. Race, ethnicity and benign prostatic hyperplasia in the Health Professionals Follow-up Study. J Urol. 2000;163:490–495
  66. Collins MF, Friedman RH, Ash A, Hall R, Moskowitz MA. Underdetection of clinical benign prostatic hyperplasia in a general medical practice. J Gen Intern Med. 1996;11:513–518
  67. Roehrborn CG, McConnell J, Jacobs S, et al. Baseline prostate volume and serum PSA predict rate of prostate growth: analysis of the MTOPS data. J Urol. 2003;169(suppl 4):364;Abstract 1361
  68. Slawin KM, Levitt JM, Lamb DJ, et al. Baseline serum BPH-A level enhances the accuracy of a nomogram to predict BPH progression in men enrolled on the GSK Phase III dutasteride trials. Presented at the 2006 American Urological Association Annual Meeting, May 20–25, Atlanta, GA. Abstract 1352. http://www.abstracts2view.com/aua_archive/view.php?nu=200696462also in print J Urol 2006 Apr;175(4 suppl):1-554. Accessed

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(08)00509-3

doi: 10.1016/j.amjmed.2008.05.023

The American Journal of Medicine
Volume 121, Issue 8, Supplement 2 , Pages S18-S26 , August 2008

Article Tools

* Image Usage & Resolution